Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Topical antifungals monograph

This article was originally published in The Tan Sheet

Executive Summary

FDA issues final rule in Feb. 8 Federal Register recognizing clotrimazole 1% as safe and effective treatment for athlete's foot (tinea pedis), jock itch (tinea cruris) and ringworm (tinea corporis) under topical antifungal drug products final monograph. Active ingredient in Schering-Plough's Lotrimin AF has been marketed OTC under an NDA since 1989. Agency estimates reg could result in one-time relabeling costs of $50,000-$75,000. FDA originally announced its intention to amend the monograph in May (1"The Tan Sheet" May 28, 2001, p. 3)...

You may also be interested in...



Schering-Plough Lotrimin AF Ingredient Monograph Status Granted

The OTC topical antifungal drug products final monograph will be amended to include clotrimazole 1%, the active ingredient in Schering-Plough Healthcare's Lotrimin AF.

Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines

Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

Pfizer's Bourla: "I Think We Forgot What It Looks Like To Grow"

The big pharma CEO reflected on his first year of leadership at Pfizer during the Forbes Healthcare Summit and talked about executing on a plan to deliver 6% growth through 2026. 

Topics

UsernamePublicRestriction

Register

PS093616

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel